Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Novavax Quadrivalent vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | - |
| Group 2 | EXPERIMENTAL | - |
| Group 3 | EXPERIMENTAL | - |
| Group 4 | EXPERIMENTAL | - |
| Group 5 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Novavax Quadrivalent vaccine | BIOLOGICAL | Quadrivalent VLP vaccine: low dose; intramuscular injection, deltoid |
| Novavax Trivalent vaccine | BIOLOGICAL | Trivalent Dose; intramuscular injection, deltoid |
| cTIV | BIOLOGICAL | Preconfigured dose; intramuscular injection, deltoid |
Inclusion Criteria: 1. Healthy adult male or females, 18-64 years of age 2. Willing and able to give informed consent prior to study enrollment 3. Able to comply with study requirements 4. Women who are not post-menopausal (≥ 50 years of age and at least one year post last menses) or surgically ste...
Novavax Quadrivalent vaccine is an investigational vaccine being developed for influenza. It is designed to generate an immune response against seasonal influenza in healthy young adults. The vaccine is currently in clinical development and has not been approved by regulatory authorities.
Novavax Quadrivalent vaccine targets influenza viruses. It is a virus-like particle vaccine intended to stimulate the immune system to recognize and respond to seasonal influenza strains. The vaccine is being studied for its ability to produce an immune response and its safety profile in healthy adults.
Novavax Quadrivalent vaccine is developed by Novavax, Inc., a biotechnology company traded on the NASDAQ under the ticker NVAX. The company is conducting clinical research to evaluate the vaccine's safety and immunogenicity for the prevention of influenza.
Novavax Quadrivalent vaccine is in Phase 2 clinical development. It is an investigational vaccine, meaning it has not been approved by regulatory agencies. The vaccine is being studied in a completed Phase 2 trial to assess its immune response and safety in healthy young adults.
Novavax Quadrivalent vaccine has one completed Phase 2 clinical trial registered as NCT01561768. This randomized, double-blind, controlled study evaluated the immune response and safety of a seasonal virus-like particle influenza vaccine in 500 healthy young adults aged 18 years and older in Australia.